1. Indications and Usage
\nFirst-Line Treatment of Non-Small Cell Lung Cancer (NSCLC):
\nIndicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.
\nNote: Patients should have their tumor tested for EGFR mutations using an FDA-approved test.
\n2. Dosage and Administration
\nRecommended Dosage:
\nAdults: 45 mg orally once daily.
\nAdministration Instructions:
\nAdminister orally without regard to food.
\nSwallow tablets whole; do not crush, break, or chew.
\nDose Modifications:
\nFirst Dose Reduction: Reduce to 30 mg once daily.
\nSecond Dose Reduction: Reduce to 15 mg once daily.
\nDose reductions are recommended based on individual safety and tolerability, particularly for severe diarrhea, skin toxicity, or interstitial lung disease (ILD).
\n3. Mechanism of Action
\nIrreversible ErbB Family Blocker:
\nDacomitinib is a small molecule, irreversible tyrosine kinase inhibitor (TKI) of human epidermal growth factor receptor (HER1\/EGFR), HER2, and HER4.
\nPhysiological Effect:
\nIt binds covalently to the catalytic domains of HER receptors, blocking downstream signaling pathways (such as Ras-Raf-MAPK, PLCgamma-PKC-NFkB, and PI3K\/AKT) that regulate tumor cell proliferation and survival.
\n4. Safety and Warnings
\nInterstitial Lung Disease (ILD):
\nFatal and severe ILD has been observed. Withhold Dacomitinib in patients with suspected ILD and discontinue permanently if ILD is confirmed.
\nDiarrhea:
\nSevere diarrhea can occur. Withhold treatment for \u2265Grade 2 diarrhea and initiate anti-diarrheal therapy (e.g., loperamide) promptly.
\nSkin Toxicity:
\nSevere skin toxicity (e.g., rash, acneiform dermatitis, paronychia) is common. Withhold treatment for persistent Grade 2 or any Grade 3\/4 skin toxicity.
\nEmbryo-Fetal Toxicity:
\nBased on its mechanism of action and animal data, Dacomitinib can cause fetal harm.
\n5. Adverse Reactions
\nMost Common:
\nDiarrhea, rash, paronychia, stomatitis (oral mucositis), decreased appetite, dry skin, weight loss, alopecia, cough, and pruritus.
\nLaboratory Abnormalities:
\nDecreased albumin, lymphopenia, anemia, increased ALT, increased AST, increased blood glucose, and hypomagnesemia.
\n6. Drug Interactions
\nProton Pump Inhibitors (PPIs):
\nConcomitant use of PPIs may decrease the solubility of Dacomitinib and reduce its bioavailability. Avoid co-administration.
\nCYP2D6 Substrates:
\nDacomitinib is primarily metabolized by CYP2D6. Concomitant use with CYP2D6 substrates may increase the concentration of the substrate, potentially leading to toxicity.
\n7. Pharmaceutical Information
\nChemical Name:
\n(2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u591a\u6cfd\u6da6\u00ae (Vizimpro\u00ae)
\nGeneric Name: Dacomitinib
\nStrength: 15 mg per tablet, 30 tablets per bottle
\nManufacturer: Pfizer Manufacturing Deutschland GmbH
\nMarketing Authorization Holder: Pfizer Europe MA EEIG\uff1b\u5883\u5185\u8d1f\u8d23\u4f01\u4e1a\uff1a\u8f89\u745e\u6295\u8d44\u6709\u9650\u516c\u53f8
\nApproval Date in China: May 17, 2019
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 HJ20190036
\nStorage: Store at 20\u201325\u2103, brief temperature excursions between 15\u201330\u2103 are permitted; keep tightly closed, protected from light and moisture, and out of reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Dacomitinib\uff08Vizimpro\uff09<\/p>\n","protected":false},"featured_media":3134,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[81],"product_cat":[27],"product_tag":[],"class_list":["post-3133","product","type-product","status-publish","has-post-thumbnail","product_brand-pfizer","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n